In the BioHarmony Drug Report Database

"Preview" Icon

Niraparib

Zejula (niraparib) is a small molecule pharmaceutical. Niraparib was first approved as Zejula on 2017-03-27. It is used to treat fallopian tube neoplasms, ovarian neoplasms, and peritoneal neoplasms in the USA. It has been approved in Europe to treat fallopian tube neoplasms, ovarian neoplasms, and peritoneal neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 1 and poly [ADP-ribose] polymerase 2. Zejula’s patents are valid until 2038-03-27 (FDA).

 

Trade Name

 

Zejula
 

Common Name

 

niraparib
 

ChEMBL ID

 

CHEMBL1094636
 

Indication

 

fallopian tube neoplasms, ovarian neoplasms, peritoneal neoplasms
 

Drug Class

 

Poly-ADP-ribose polymerase inhibitors

Image (chem structure or protein)

Niraparib structure rendering